Nurix Therapeutics (NRIX) Common Equity (2019 - 2025)
Historic Common Equity for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $538.7 million.
- Nurix Therapeutics' Common Equity rose 223.04% to $538.7 million in Q4 2025 from the same period last year, while for Nov 2025 it was $538.7 million, marking a year-over-year increase of 223.04%. This contributed to the annual value of $538.7 million for FY2025, which is 223.04% up from last year.
- Per Nurix Therapeutics' latest filing, its Common Equity stood at $538.7 million for Q4 2025, which was up 223.04% from $372.3 million recorded in Q3 2025.
- In the past 5 years, Nurix Therapeutics' Common Equity ranged from a high of $538.7 million in Q4 2025 and a low of $168.7 million during Q1 2024
- In the last 5 years, Nurix Therapeutics' Common Equity had a median value of $342.4 million in 2021 and averaged $342.8 million.
- As far as peak fluctuations go, Nurix Therapeutics' Common Equity tumbled by 3842.48% in 2024, and later soared by 18499.12% in 2025.
- Nurix Therapeutics' Common Equity (Quarter) stood at $342.3 million in 2021, then fell by 11.28% to $303.7 million in 2022, then crashed by 33.98% to $200.5 million in 2023, then soared by 162.85% to $527.0 million in 2024, then rose by 2.23% to $538.7 million in 2025.
- Its last three reported values are $538.7 million in Q4 2025, $372.3 million for Q3 2025, and $447.6 million during Q2 2025.